University of Utah PS-IDE: Physician Modified Endovascular Grafts for the Treatment of Elective, … (NCT07065760) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
University of Utah PS-IDE: Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysms
United States15 participantsStarted 2025-08-01
Plain-language summary
The purpose of this study is to assess the effects of a physician-modified endovascular graft (PMEG) for juxtarenal aortic aneurysms by collecting data on its performance. Participants in the study will undergo surgery to repair their juxtarenal aortic aneurysm using the PMEG device. After the surgery, participants will attend several follow-up visits to monitor their recovery and the device's effectiveness. These follow-up visits will take place at hospital discharge, then at 1 month, 6 months, 12 months, and once a year for up to 5 years after surgery.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patient is ≥ 18 years of age
✓. Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study)
✓. Patient or Legally Authorized Representative has signed an Institutional Review Board (IRB) approved Informed Consent Form
✓. Patient has a juxtarenal abdominal aortic aneurysm that meets at least one of the following:
✓. An aneurysm with a maximum diameter of ≥ 5.5 cm for male (≥ 5.0 cm for female) or 2 times the normal diameter just proximal to the aneurysm using orthogonal (i.e., perpendicular to the centerline) measurements
✓. Aneurysm with a history of growth \> 0.5 cm in 6 months
✓. Saccular aneurysm deemed at significant risk for rupture
✓. Symptomatic aneurysm
Exclusion criteria
✕. Patient has a mycotic aneurysm or has an active systemic or local infection that may increase the risk of endovascular infection
✕. Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina)
✕. Patient has a major surgical or interventional procedure, not related to the endovascular repair, planned within +/- 30 days of the AAA repair.
✕. Patient has history of an aortopathic connective tissue disease (e.g. Marfan's or Ehler's-Danlos syndrome).
✕. Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment.
✕. Patient has known allergy or intolerance to stainless steel, nitinol or gold (gold-coated tungsten).
✕. Patient has a body habitus that would inhibit X-ray visualization of the aorta
✕. Patient has a limited life expectancy of less than 1 year